Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + vistusertib
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
A combination therapy consisting of fulvestrant, a selective estrogen receptor degrader (SERD), and vistusertib (AZD2014), a dual inhibitor of mTORC1 and mTORC2. This combination was investigated for the treatment of hormone receptor-positive (HR+) breast cancer, particularly in patients with resistance to endocrine therapy.
- Brand names
- Faslodex (for fulvestrant)
- Other names
- AZD2014 + faslodexvistusertib + fulvestrant
02
Targets
Mechanistic target of rapamycin kinase complex 2ESR1 (ERα)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on fulvestrant + vistusertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + vistusertib.